Features of the Course and Principles of Treatment of Pregnant Women with Antiphospholipid Syndrome

Authors

  • Muratova Nigora Djuraevna Doctor of Medical Sciences, Professor, Departments of Obstetrics and Gynecology, Tashkent State Dental Institute
  • Shokirova Nargiza Ganiyevna Resident physician, Departments of Obstetrics and Gynecology, Tashkent State Dental Institute

Keywords:

antiphospholipid syndrome, pregnancy, prevention of exacerbations

Abstract

The factors influencing the outcome of pregnancy, the development of an undeveloped pregnancy, and miscarriages were analyzed, and the risks of possible complications of rheumatic diseases in this category of patients were assessed. Special attention is paid to the issues of planning and preparation for pregnancy. The tactics of managing pregnant women with AFS and the dosage regimen largely depend on the previous medical history (the presence/ absence of non-placental thrombosis, the number of spontaneous abortions, an undeveloped pregnancy, and previous therapy). In this regard, the article identifies clinical groups with different types of therapy.

References

Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for define antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 2006, vol. 4, no. 2, pp. 295- 306.

Tsirigotis P., Mantzios G., Pappa V. et al. Antiphospholipid syndrome: a predisposing factor for early onset HELLP syndrome. Rheumatology International, 2007, vol. 28, no. 2, pp. 171-174.

Gomez-Puerta J., Cervera R., Espinosa G. et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Annals of the Rheumatic Diseases, 2007, vol. 66, no. 6, pp. 740-746.

Ruffatti A., Calligaro A., Hoxha A. et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care & Research, 2010, vol. 62, no. 3, pp. 302-307.

Boffa M.C., Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibody: a review. Lupus, 2007, vol. 16, no. 8, pp. 634-641.

Mekinian A., Lachassinne E., Nicaise-Roland P. et al. European registry to babies born to mothers with antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2013, vol. 72, no. 2, pp. 217-222.

Lockshin M.D., Kim M., Laskin C.A. et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibody. Arthritis & Rheumatology, 2012, vol. 64, no. 7, pp. 2311-2318.

Ruffatti A., Tonello M., Del Ross T. et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thrombosis and Haemostasis, 2006, vol. 96, no. 3, pp. 337-341.

Danowski A., de Azevedo M.N., de Souza Papi J.A. et al. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and antiphospholipid syndrome with systemic lupus erythematosus. Journal of Rheumatology, 2009, vol. 36, no. 6, pp. 1195-1199.

Gris J.C., Perneger T.V., Quere I. et al. Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood, 2003, vol. 102, pp. 3504-3513.

Salmon J.E., Girardi G., Holers N.M. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus, 2003, vol. 12, no. 7, pp. 535-538.

Cowchock F.S., Reece E.A., Balaban D. et al. Repeated fetal losses associated with antiphospholipid antibody: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. American Journal of Obstetrics and Gynecology, 1992, vol. 166, no. 5, pp. 1318-1323.

Rai R., Cohen H., Dave M. et al. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibody (or antiphospholipid antibody). British Medical Journal, 1997, vol. 314, pp. 253-256.

Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology, 1996, vol. 174, no. 5, pp. 1584- 1589.

Ziakas P.D., Pavlou M., Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstetrics & Gynecology, 2010, vol. 115, no. 6, pp. 1256-1261.

Downloads

Published

2025-04-24

How to Cite

Djuraevna, M. N., & Ganiyevna, S. N. (2025). Features of the Course and Principles of Treatment of Pregnant Women with Antiphospholipid Syndrome. International Journal of Alternative and Contemporary Therapy, 3(4), 62–65. Retrieved from https://medicaljournals.eu/index.php/IJACT/article/view/1748